GlassScriptPhysician profile
Britne Simpson
NPI 1306300355
$4,446.15
in general payments reported to CMS, 2019-2025
15 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $578 · 2023: $1,374 · 2024: $1,137 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,247.10 | 2022-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $847.66 | 2023-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $556.44 | 2023-2025 | Proclaim, Eterna |
| Abbvie INC. | $509.65 | 2023-2025 | |
| Pfizer INC. | $367.28 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $273.17 | 2023-2024 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $219.46 | 2022-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $156.01 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $78.55 | 2022 | |
| Lilly USA, LLC | $54.73 | 2024 | Emgality, Reyvow |
| Almatica Pharma LLC | $42.38 | 2023 | Gralise |
| Vertex Pharmaceuticals Incorporated | $40.21 | 2025 | |
| Merz Pharmaceuticals, LLC | $24.28 | 2025 | Xeomin |
| Fidia Pharma USA INC. | $14.91 | 2023 | Triluron, Hymovis |
| Hikma Pharmaceuticals USA | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britne Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.